Design of high-specificity binders for peptide–MHC-I complexes

Class I major histocompatibility complex (MHC-I) molecules present peptides derived from intracellular antigens on the cell surface for immune surveillance. Proteins that recognize peptide-MHC-I (pMHCI) complexes with specificity for diseased cells could have considerable therapeutic utility. Specificity requires recognition of outward-facing amino acid residues within the disease-associated peptide as well as avoidance of extensive contacts with ubiquitously expressed MHC. We used RFdiffusion to design pMHCI-binding proteins that make extensive contacts with the peptide and identified specific binders for 11 target pMHCs starting from either experimental or predicted pMHCI structures. Upon incorporation into chimeric antigen receptors, designs for eight targets conferred peptide-specific T cell activation. Our approach should have broad utility for both protein- and cell-based pMHCI targeting.

Authors

Institutions

Publication Details

Journal
Science
Published
2025-07-24
DOI
https://doi.org/10.1126/science.adv0185
Citations
29
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
23.13
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design of high-specificity binders for peptide–MHC-I complexes

Nathan Greenwood, David A. Scheinberg, Xinyu Xiang, K. Christopher García et al.
29 citations
Science
Immunotherapy and Immune Responses
23.13
article

Design of high-specificity binders for peptide–MHC-I complexes

Nathan Greenwood, David A. Scheinberg, Xinyu Xiang, K. Christopher García, Gian Marco Visani, Bingxu Liu, Dionne Vafeados, Amir Motmaen, David A. Baker, Tao Dao, Russell Ault, Armita Nourmohammad, Jeremy Meyerberg, Chunyu Wang, J. M. Sharp, Nicole Roullier, Julia E. Bonzanini
article en
29 citations

Abstract

Class I major histocompatibility complex (MHC-I) molecules present peptides derived from intracellular antigens on the cell surface for immune surveillance. Proteins that recognize peptide-MHC-I (pMHCI) complexes with specificity for diseased cells could have considerable therapeutic utility. Specificity requires recognition of outward-facing amino acid residues within the disease-associated peptide as well as avoidance of extensive contacts with ubiquitously expressed MHC. We used RFdiffusion to design pMHCI-binding proteins that make extensive contacts with the peptide and identified specific binders for 11 target pMHCs starting from either experimental or predicted pMHCI structures. Upon incorporation into chimeric antigen receptors, designs for eight targets conferred peptide-specific T cell activation. Our approach should have broad utility for both protein- and cell-based pMHCI targeting.

ScienceVol. 389(6758)
Memorial Sloan Kettering Cancer Center (US), Children's Hospital of Philadelphia (US), Howard Hughes Medical Institute (US), University of Washington (US), Cornell University (US), Fred Hutch Cancer Center (US), University of Washington Applied Physics Laboratory (US), Weill Cornell Medicine (US), University of Pennsylvania (US), Stanford University (US)
Good health and well-being
Openalex Percentile: Top 0%
Immunotherapy and Immune Responses
23.13
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.